Top Stories News

An HHS report cites fraud by drug and device makers.

The Indian pharma industry saw a 16.5 percent upswing in 2010 sales. The growth was fueled by Big Pharma as much as by domestic drugmakers.

Furiex Pharmaceuticals' MuDelta program has been granted Fast Track designation by the FDA.

Israel's drug maker Teva Pharmaceutical Industries has launched a lawsuit in London to revoke the European patent for Seroquel, paper reports.

The future cost to cure heart disease in the U.S. will triple by 2030, according to the American Heart Association.

In the past five years, several contaminated pharmaceutical products have led to patient injuries and deaths globally. The emphasis on the linkage between supplier control and risk management will continue to increase.

The Securities and Exchange Commission announced it has obtained a court order freezing the bank and brokerage accounts controlled by an individual who made more than $800,000 in illegal profits by trading on inside information tipped to him by an empl...

AstraZeneca says it remains confident in the NDA submission for ticagrelor and will continue to work with the FDA to progress towards the completion of the review.

CHMP recommended that Gilenya 0.5 mg daily could be used as a therapy for patients with highly active relapsing-remitting MS.

Pharmaceutical manufacturer Perrigo hopes the transaction will add more than $200 million to its annual sales during its first fiscal year.

Branded drugs are expected to slow their sales growth to a very low stage due to patent losses.

The European Commission has requested the Agency’s Committee for Medicinal Products for Human Use assess all available data concerning the possible risks of liver injury.

Companies in the U.S. are reviewing their options and considering reductions for the employee health care benefits due to the health care reform.

Our body needs to be in balance with its systems under normal functions. One of those major regulatory systems in the body is the Endocrine System.

A new pharmaceutical plant will be built by Genzyme for larger production capacity to satisfy the growing need for Myozyme and Lumizyme.

Sanofi-Aventis’ offer for biotech firm Genzyme ends this Friday. The deadline is likely to be extended once again and the offer may see an increase towards USD80 per share.

Two trade associations representing innovative bioscience companies in the UK and New Zealand have established their alliance to dedicate more to bioscience companies.

Looking over the top 10 biotech IPOs of 2010, the best performer doesn't actually have a pipeline of therapeutics. But for the year of 2011, investors will have their biotech dreams set on best products.

A programme launched in India by WHO aims to promote students' reasonable adoption of medicines.

Sanofi-Aventis and Famar expands their cooperation as a new agreement has been set for a manufacturing plant in Madrid.

The establishment of the Alzheimer's Foundation of Israel highlights the worldwide attention to Alzheimer's crisis and is an international commitment to deliver better care and treatment for Alzheimer's population in Israel.

Due to concerns about potential contamination of the Triad Group’s products, Genentech recalls alcohol prep pads.

Sanofi-Aventis and Genzyme are debating their terms for a transaction which analyst believes has a chance of being reached before before Jan. 21 when Sanofi's current offer expires.

A new public health initiative for people with type 2 diabetes mellitus called The Type 2 Talk will be launched in America to help people actively manage their disease.

GlaxoSmithKline has a partnership deal with Epizyme who will help GSK discover small molecule drugs for enzymes called histone methyltransferases.

Merck KGaA has acquired 100% of the share capital of Beijing Skywing Technology Co., Ltd., a leading supplier of cell-culture media products, related technical services and bioreactors in China.

2010 was a big year for pharma layoffs, plant closures and other sorts of cutbacks. But some new stats suggest that it wasn't quite as bad as 2009.

Santaris Pharma and Pfizer have expanded their collaboration for the development and commercialization of RNA-targeted medicines using Santaris Pharma’s Locked Nucleic Acid (LNA) drug platform.

Patients with cirrhosis are at a significantly higher risk of cancer and a new study by U.S. researchers adds to what's already known about those risks.

2010 will not go down in biotech history as a particularly fruitful year for new drug approvals.

Spooked by recent buyouts, Indian officials are weighing a new cap on foreign investment in domestic companies.

The US FDA has approved a clear, odorless testosterone gel that is applied directly to the front and inner thigh.

If 2009 was the year of the mega-merger, 2010 was the year of continuing R&D reorganization, downsizing and evolution.

Chris Viehbacher wasn't playing around when he said that Sanofi-Aventis ($SNY) was going to turn to outside partners for more of its innovative thinking.

Every year everybody who's anybody in biotech--and a lot who aren't--goes to the JP Morgan conference in San Francisco in January.

Every year brings a new discussion of whether the FDA is getting tougher. This year the question was just how much tougher regulators have become under the Obama administration.

The emerging-markets gold rush continues. Drugmakers continued their race into those fast-growing, tantalizing new markets. India, China, Brazil, Russia, Mexico.

Recent breakthroughs show that China is emerging as a world leader in stem-cell research and development, says Emerging Healthcare Solutions President and CEO Cindy Morrissey.

Arena Pharmaceuticals and its partners at Eisai have had a chance to review exactly what the FDA wants to see on their experimental weight drug.

Some Johnson & Johnson ($JNJ) investors have resorted to court action, saying that directors and executives not only ignored 'red flags' that something was rotten within J&J, but allowed the company's once-stellar reputation to be destroyed.

Novartis latest product, the multiple sclerosis treatment Gilenya, has already been hailed as a prospective blockbuster.

For the second time in two months, we're seeing reports that Chinese officials are planning to lower drug prices.

Novartis' pledged to invest $500 million in Russian manufacturing, R&D and public health.

According to a new report, drugmakers defraud the federal government more than any other business.

Roche confirmed that following the reviews of Avastin (bevacizumab) in metastatic breast cancer by EMA) and FDA, the following regulatory announcements were made by the individual health authorities.

GE Healthcare today announced the expiration of the initial offering period of the previously announced tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc..

Indian drugmakers are aiming to team up with China in a bid to outpace western drugmakers who've been scrambling to grab market share in both countries.

The outgoing chief of the European Medicines Agency concluded that the $85 billion the industry spends on drug R&D each year is simply wasted.

GlaxoSmithKline is splashing out UKpound162m on a protein drinks maker, but signalled that a lack of cheap takeover deals could see the drugs giant re-start its multi-billion pound share-buyback programme.

A recent analysis published by THE SAGE GROUP concluded that 3 million people in Western Europe have critical limb ischemia (CLI).

Bayer HealthCare is building a new facility center in Wuppertal on an area of some 1,000 square meters for the biotechnological production of pharmaceuticals to be used in clinical trials.

Illegal online drug sellers have provided tens of millions of Americans prescription medication via the Internet without a valid prescription, recent research has found.

New data shows that Xgeva (denosumab) delayed the spread of prostate cancer into bone, and that's set the oncology world abuzz.

Negotiators say India will withdraw its complaint filed at the World Trade Organization, now that it has reached an agreement with E.U. trade police.

Genzyme Corp. today reiterated the unanimous recommendation of its board of directors.

Sanofi-Aventis' ($SNY) lowball bid for Genzyme ($GENZ) is set to expire at midnight tonight.

The BioIndustry Association welcomes the publication today of the latest government statistics highlighting the growth of the UK's innovative bioscience sector.

Russia has been rumbling at global pharma for awhile, but Prime Minister Vladimir Putin has sharpened his warnings to foreign drugmakers.

Pharma M&A is up by 20 percent so far this year as drugmakers scramble to refill depleted pipelines, push into emerging markets and diversify beyond prescription drugs.

In what is likely to prove a shocker for many FDA watchers, the agency's expert advisors voted 13 to 7 in favor of approving Orexigen's obesity drug Contrave.

Merck KGaA is supporting the World Health Organization (WHO) in the fight against the neglected tropical disease schistosomiasis.

The Bayer Group aims to invest its resources as a whole more consistently in growth and innovation capability. 'We have a very successful record in innovation,' Management Board Chairman Dr. Marijn Dekkers said.

China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca.

Focus on cancer vaccines, auto-immune disease diagnostics and treatment

As time runs down on Sanofi-Aventis' $69-per-share offer for Genzyme --the offer expires Dec. 10--both sides are still far apart on an agreement.

The steady drumbeat of downbeat manufacturing news and recalls has heightened worries among market-watchers.

Genzyme Corporation has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash.

Bristol-Myers Squibb Company and Alvin Ailey American Dance Theater announced the launch of the 2011 REYATAZ? (atazanavir sulfate) 'Fight HIV Your Way' contest.

China is working on a step-by-step reduction in drug prices that previously had been excused from the government's controls.

The New England Journal of Medicine is weighing in on social media.

Merck KGaA announced that the U.S. Food and Drug Administration has extended its review period for Cladribine Tablets.

FDA extended the review to 'provide additional time for a full review of additional information provided under the new drug application.'

Abbott (NYSE: ABT) has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group.

Johnson & Johnson ($JNJ) execs should write a blues song about recalls.

Stelmi has created a technical centre at its headquarters near Paris, which will be operational early next year.

UK-based Honeyman Group will open a pharmaceutical training facility in February 2011.

The FDA has released its latest list of scarce drugs, and several cancer drugs are included.

Privacy advocates are asking the Federal Trade Commission to investigate how that information is used in drug marketing.

Roche is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals, according to the UK biotech.

Animal rights activists have claimed responsibility for sending a package of razor blades to a UCLA researcher involved in animal studies.

Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree.

UK biopharmaceutical firm Xention has raised ?8m in private equity funding to advance the development of drugs to treat atrial fibrillation.

WHO has said the little-used World Trade Organisation (WTO) licensing system for generic medicines during health emergencies may actually become useful.

Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September.

Half of Europeans using the Internet for health information are interested in online patient education programs from pharmaceutical companies.

Chris Brinsmead, chairman of AstraZeneca Pharmaceuticals UK, has become the UK government’s life sciences business adviser.

The National Lipid Association announced the recent acceptance of its journal for indexing in PubMed and MEDLINE by the U.S. National Library of Medicine.

Johnson & Johnson has been hit with another recall, but this time J&J wasn't the company overseeing production.

Roche singled out its work in RNAi when choosing its R&D targets for the budget axe, announcing plans to shutter the work underway in Kulmbach, Germany, Nutley, NJ and Madison, WI.

Despite rumors, GlaxoSmithKline's senior vice president of medicines discovery and development, says his company isn't considering a bid for Genzyme.

Approved as an osteoporosis treatment--sold under the brand name Prolia--the drug got the FDA nod for fracture prevention in certain cancer patients.

At CPHI Worldwide 2010, Cargill announced a new pharmaceutical patent application for Zerose? erythritol.

Attendees up by 14%,* Exhibitor Numbers Increase to 1934.

Shares of Human Genome Sciences had been trimmed 11 percent as investors fretted over the implications of an FDA staff analysis of its lupus drug Benlysta.

The U.S. FDA approved Halaven to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

For all the promise of tweaking the healthcare reform law in pharma-friendly ways, there's now a counterweight to those very plans.

Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight.

Roche has failed to get the cancer drug Avastin on the National Health Service formulary for colorectal-cancer treatment.

Bristol-Myers Squibb Foundation launches $100 million initiative targeting America's type 2 diabetes crisis.

Nycomed's strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pan...

Advaxis was awarded a Qualifying Therapeutic Discovery Project credit from the Federal Government for ADXS11-001.

Apparently, Novartis ($NVS) has done just that, using professional athletes as a draw at doctor dinners.

China Medicine Corporation today announced financial results for the third quarter ended September 30, 2010.

FDA Commissioner Margaret Hamburg is trying to forestall any talk of cutting her agency's funding.

Program to Provide Full Regulatory Support for Clients' Clinical Development Programs Under Experienced Leadership.

Sanofi-aventis has sent a letter to Genzyme Corporation requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9.

PhRMA still has its eyes on healthcare reform.In fact, PhRMA spent some big bucks to back candidates who supported healthcare reform the first time around.

The US Food and Drug Administration (FDA) approved KOMBIGLYZE? XR for the treatment of type 2 diabetes in adults.

Apricus Bio will use the proceeds of the grant funds to continue development of PrevOnco?, RayVa? and Femprox?.

Allergan is gearing up to promote Botox as a migraine-fighter, a newly approved use for the wrinkle-fighting, muscle-relaxing drug.

Chinese officials gave the go-ahead to Sanofi-Aventis' ($SNY) joint venture with Hangzhou Minsheng Pharmaceutical Group.

As healthcare and pharma experts are finding that the Washington power shift will present some new challenges.

Pfizer Inc. reported financial results for third-quarter 2010.

The U.S. Justice Department saying that unmodified DNA should not be patentable.

Waksal told that his new biotech company will be bigger and better than ImClone ever was.

This time driving a Pfizer recall of the cholesterol-fighting blockbuster Lipitor.

Drugmakers may be focusing on smaller deals this year, rather than the megamergers of 2009, but those smaller buys do add up.

The World Health Organisation (WHO) says four major medicine companies are backing an initiative to boost the flow of pharmaceuticals fighting lower profile tropical diseases.

UK pharmaceutical manufacturer GlaxoSmithKline (GSK) has licensed a treatment for Fabry disease from Amicus Therapeutics.

GlaxoSmithKline and its subsidiary SB Pharmco have agreed to pay $750 million to resolve criminal and civil allegations relating to the manufacturing and sale of certain adulterated drugs.